iBio Clinical Trial Data
iBio announced extended preclinical data from a non-human primate study of IBIO-610, showing a 2.3% reduction in body weight and significant fat mass reduction over 28 weeks while maintaining lean mass. The company also disclosed preclinical data for its amylin program demonstrating selective receptor activation and reduced food intake in rat models. These results highlight the efficacy of iBio's AI-enabled antibody discovery platform in targeting obesity and cardiometabolic diseases.